好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Precision-mapping Functional Connectivity in Parkinson Disease: Feasibility & Reliability
Movement Disorders
P7 - Poster Session 7 (11:45 AM-12:45 PM)
3-005

To determine the feasibility and reliability of using precision-mapping techniques for people with Parkinson disease.

Standard resting-state functional connectivity (RSFC) approaches collect small amounts of data, typically ≤ 10 min, and rely on group-average network definitions. An innovative new approach applies precision-mapping techniques, with > 40min of data, to identify individual-level RSFC network maps. Precision-mapping RSFC reveals individual differences in network size, strength, and location. 

We tested the feasibility and reliability of precision-mapping RSFC for people with Parkinson disease. Participants completed multiple fMRI sessions (3-5) up to seven months apart. Using stringent motion censoring, we determined the amount of low-motion, high quality fMRI data per person to establish feasibility. We compared the similarity of RSFC maps across sessions to examine stability and applied split-half analyses to measure the reliability of RSFC maps based on amount fMRI data.

Preliminary analyses reveal the high feasibility and strong reliability of precision-mapping RSFC for people with Parkinson disease. All participants completed multiple fMRI sessions with large amounts of low motion data for each person (>40 min per person, frame retention average = 75%). Individual participant RSFC maps were stable across sessions (r > 0.7) and highly reliable with >40min of data (split-half reliability, r > 0.8).

These results demonstrate the feasibility and reliability of using the precision-mapping technique for identifying individual-level RSFC networks in Parkinson disease.  With this approach, it will now be possible to examine how individual-level variability of RSFC networks relates to variability in clinical manifestations and predicts progression of Parkinson disease.

Authors/Disclosures
Meghan C. Campbell, PhD (Washington University in St. Louis)
PRESENTER
The institution of Meghan C. Campbell has received research support from NIH. The institution of Meghan C. Campbell has received research support from NIH. The institution of Meghan C. Campbell has received research support from McDonnell Center for Systems Neuroscience. The institution of Meghan C. Campbell has received research support from WUSM Radiology Department. The institution of Meghan C. Campbell has received research support from NIH. Meghan C. Campbell has received personal compensation in the range of $0-$499 for serving as a Grant Reviewer with Parkinson Foundation. Meghan C. Campbell has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with Department of Defense.
Sarah Grossen Sarah Grossen has nothing to disclose.
Emma Carr (Washington University in St. Louis - School of Medicine) No disclosure on file
Abdulmunaim Eid, MD Dr. Eid has nothing to disclose.
Scott Norris, MD (Washington University School of Medicine) The institution of Dr. Norris has received research support from NIH, DMRF, Dysphonia International.
No disclosure on file
Ally Dworetsky No disclosure on file
Caterina Gratton (FLORIDA STATE UNIVERSITY) No disclosure on file